阿玛琳 AMRN 深 沪
等待开盘 04-02 09:30:00 美东时间
14.64
+0.180
+1.24%
华盛通- 最 高14.90
- 今 开14.46
- 成交量 2.52万股
- 最 低 14.41
- 昨 收 14.46
- 总市值 3.05亿
- 52周最高 20.90
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 8.32
- 委 比 38.31%
- 总股本 2080.40万
- 历史最高 522.40
- 量 比 0.51
- 振 幅 3.39%
- 历史最低 7.08
- 每 手 1
- 风险率 2.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
Amarin shares are trading lower after the company reported a Q4 sales miss.
Amarin shares are trading lower after the company reported a Q4 sales miss.
02-26 01:24
Amarin Corp Earnings Report: Q4 Overview
Amarin Corp (NASDAQ:AMRN) announced its Q4 earnings on Wednesday, February 25, ...
02-25 20:04
Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.56) by 101.79 percent. This is a 150 percent increase over losses of $(0.02) per share from the
02-25 20:03
Earnings Scheduled For February 25, 2026
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
Amarin Reports $217M Revenue and $303M Cash in Preliminary Full-Year 2025 Results
Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025
01-08 20:14
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
Amarin Corporation plc reported strong financial performance in 2025, achieving positive cash flow in Q4 and ending the year with a cash balance of $303 million. They sustained market leadership in the U.S. for VASCEPA, with over 50% of IPE prescriptions, and expanded their presence in Europe through a partnership with Recordati, commercializing VAZKEPA in 59 countries. The company also secured regulatory approvals in South Korea and Singapore. W...
01-08 12:00
Amarin To Present New Data Highlighting VASCEPA's Cardiovascular Benefits And EPA's Anti-Inflammatory, Antioxidant Mechanisms At AHA 2025
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana.
2025-11-03 21:41
Amarin shares are trading lower. The company reported Q3 financial results.
Amarin shares are trading lower. The company reported Q3 financial results.
2025-10-30 02:22
Amarin Corp Q3 2025 Adj per ADS $0.19 Up From $(1.00) YoY, Sales $49.670M Beat $43.099M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.19 per share. This is a 119 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $49.670
2025-10-29 19:17
